An anti-SARS-CoV-2 metabolite is reduced in diabetes

dc.contributor.author	Vergara-Alert, Júlia
dc.contributor.author	Izquierdo-Useros, Nuria
dc.contributor.other	Producció Animal	ca
dc.date.accessioned	2022-09-26T11:35:22Z
dc.date.available	2022-11-05T23:45:15Z
dc.date.issued	2022-05-09
dc.identifier.citation	Vergara-Alert, Júlia, and Nuria Izquierdo-Useros. 2022. "An Anti-SARS-Cov-2 Metabolite Is Reduced In Diabetes". Nature Metabolism 4 (5): 501-502. doi:10.1038/s42255-022-00569-x.	ca
dc.identifier.issn	2522-5812	ca
dc.identifier.uri	http://hdl.handle.net/20.500.12327/1902
dc.description.abstract	A glucose-like metabolite, which is reduced in the serum of diabetic patients, inhibits the entry of SARS-CoV-2 into key cellular targets. The work led by Cheng and colleagues provides a molecular explanation for the increased risk of severe COVID-19 in patients with diabetes.	ca
dc.format.extent	4	ca
dc.language.iso	eng	ca
dc.publisher	Nature Research	ca
dc.relation.ispartof	Nature Metabolism	ca
dc.rights	Copyright © 2022, Springer Nature Limited	ca
dc.title	An anti-SARS-CoV-2 metabolite is reduced in diabetes	ca
dc.type	info:eu-repo/semantics/article	ca
dc.description.version	info:eu-repo/semantics/acceptedVersion	ca
dc.rights.accessLevel	info:eu-repo/semantics/openAccess
dc.subject.udc	619	ca
dc.identifier.doi	https://doi.org/10.1038/s42255-022-00569-x	ca
dc.contributor.group	Sanitat Animal	ca